Bristol-Myers Squibb | BMY - Des Atouts

Prix De L'Action
60.67
Variation Quotidienne
0.96 1.61%
Mensuellement
1.57%
Annuel
1.29%
Q1 Prévisions
57.30




Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Abbott USD 86.71B 2.53B 2025-12
ALKERMES USD 2.49B 157.48M 2025-12
Amgen USD 90.59B 445M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
Biogen USD 29.44B 232M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Coherus Biosciences USD 258.34M 258.18M 2025-12
Drreddys Laboratories INR 6.26B 161.9M 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
J&J USD 199.21B 6.39B 2025-12
Medtronic USD 91.35B 374M 2025-09
Merck USD 129.55B 12.02B 2025-09
Novartis USD 107.29B 2.89B 2025-09
Novo Nordisk DKK 542.9B 30.61B 2025-12
Perrigo USD 8.54B 1.55B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Phibro Animal Health USD 1.41B 20.03M 2025-12
Prestige Brands USD 3.49B 52.46M 2025-12
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 126.81B 2.99B 2025-12
Sanofi EUR 126.81B 25.48B 2025-12
United Therapeutics USD 7.88B 528.9M 2025-12
Zoetis USD 15.47B 308M 2025-12